Search Results: BRCA

• For Researchers

The power of genomic cancer data

We're working with Public Health England to promote the collection and usage of genomic cancer data; the National Lung Matrix Trial highlights the benefits. We're working with Public Health England to promote the collection and usage of genomic cancer data; the National Lung Matrix Trial highlights the benefits.

15 July 2020

• Health & Medicine

Breast and ovarian cancer drug effective in advanced prostate cancer

A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer. A targeted cancer drug, already licensed for treating some breast and ovarian cancers, is found to be effective for some men with advanced prostate cancer.

1 May 2020

• Health & Medicine

Three new treatment options approved for NHS use in Scotland

The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland The Scottish Medicines Consortium (SMC) has accepted 3 new cancer treatments for NHS use in Scotland

26 March 2020

• Health & Medicine

Research suggests statins could lower ovarian cancer risk

A genetic study has found evidence to suggest that women who take statins in the long term could be less likely to develop ovarian cancer. A genetic study has found evidence to suggest that women who take statins in the long term could be less likely to develop ovarian cancer.

18 February 2020

• Science & Technology
• Health & Medicine

News digest – ex-smokers’ lungs, NHS staff shortages, Brexit and breast cancer genes

In the news this week: protective cells lining the lungs of ex-smokers could explain why quitting smoking reduces lung cancer risk. In the news this week: protective cells lining the lungs of ex-smokers could explain why quitting smoking reduces lung cancer risk.

1 February 2020

• Health & Medicine

Targeted ovarian cancer drug made available to more people on NHS in England

NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England. NICE has made olaparib (Lynparza), a targeted cancer drug, more widely available for people with ovarian cancer on the NHS in England.

11 December 2019

• Health & Medicine

Targeted ovarian cancer drug made more widely available on the NHS in Scotland

A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy. A targeted cancer drug has been approved for use on the NHS in Scotland for patients with newly diagnosed ovarian cancer that’s responded to chemotherapy.

9 December 2019

• Science & Technology

So-called 'junk DNA' affects inherited cancer risk

Research reveals how genetic variations in the regions of DNA that don't code for proteins, once dismissed as 'junk DNA', can affect a person's risk of cancer. Research reveals how genetic variations in the regions of DNA that don't code for proteins, once dismissed as 'junk DNA', can affect a person's risk of cancer.

6 December 2019

• Science & Technology
• Health & Medicine

News digest – breast cancer survival, melanoma immunotherapy, red meat and cigarette warnings 

In the news this week: record numbers of people beating breast cancer and long-term benefits of melanoma immunotherapy revealed. In the news this week: record numbers of people beating breast cancer and long-term benefits of melanoma immunotherapy revealed.

5 October 2019

• Science & Technology
• Health & Medicine

News digest – ‘sugar tax’ success, Scottish drug decisions, smoking rates and an 'electronic nose'

In the news this week: an ‘electronic nose’ could help predict who may benefit from lung cancer immunotherapy. In the news this week: an ‘electronic nose’ could help predict who may benefit from lung cancer immunotherapy.

21 September 2019

• Health & Medicine

Advanced ovarian cancer drug gets initial ‘no’ for NHS in England

A targeted drug with potential to slow the progress of ovarian cancer has been rejected for use on the NHS in England. A targeted drug with potential to slow the progress of ovarian cancer has been rejected for use on the NHS in England.

9 August 2019

• Health & Medicine

Ovarian cancer drug will be offered earlier to NHS patients in England

A targeted drug for advanced ovarian cancer will be more widely available for certain patients on the NHS in England. A targeted drug for advanced ovarian cancer will be more widely available for certain patients on the NHS in England.

26 July 2019